Hironori Fukuda
Papers
1
Total Citations
5
H-Index
1
About
Hironori Fukuda is a leading urologic oncologist whose research focuses on advanced renal cell carcinoma (RCC), particularly cases complicated by inferior vena cava (IVC) tumor thrombus. His major contribution lies in pioneering neoadjuvant immunotherapy-based strategies for surgically complex RCC. Notably, his landmark 2024 study on combining lenvatinib and pembrolizumab prior to surgery demonstrated that this regimen can safely downstage IVC tumor thrombi, potentially converting inoperable cases into resectable ones—a breakthrough for a condition historically associated with poor prognosis. This work, already garnering 5 citations shortly after publication, addresses a critical gap in managing high-risk RCC with venous involvement. Dr. Fukuda’s research bridges medical oncology and surgical innovation, offering new hope for patients with locally advanced disease. His findings are reshaping perioperative treatment paradigms, emphasizing the role of targeted therapy and immunotherapy combinations in reducing tumor burden before high-risk thrombectomy. For researchers and clinicians, his work represents a vital step toward personalized, multidisciplinary management of aggressive RCC.
Research Focus
Key Achievements
Top Papers
- 1